3B Pharmaceuticals

3B Pharmaceuticals is a German biotech specializing in targeted radiopharmaceuticals for cancer diagnosis and therapy. The company has built a diversified pipeline targeting pan-tumor antigens like FAP, as well as NTR1, CAIX, and GIP receptors, with key assets partnered with major players like Novartis and Debiopharm. Operating as a private, R&D-focused entity, 3B leverages its proprietary platform to develop novel radioligands, positioning itself in the rapidly growing field of precision oncology and theranostics.

Proprietary platform for discovering and developing peptide-based radiopharmaceuticals that target tumor-associated antigens (e.g., FAP, NTR1, CAIX, GIP receptor) for diagnostic imaging and targeted radiotherapy.

The radiopharmaceutical field is highly competitive, with major players like Novartis, Bayer, and Point Biopharma advancing targeted radioligand therapies. For FAP specifically, 3B faces competition from companies like Siemens Healthineers and others developing FAP-targeting diagnostics and therapeutics.